Merck KGaA Says FDA Extends Review of Multiple Sclerosis Pill, Caldribine in Setback for Novartis AG

November 29, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Bloomberg -- U.S. regulators extended the review period for Merck KGaA’s cladribine multiple sclerosis pill by three months, a setback for the drugmaker in the race with Swiss rival Novartis AG.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Europe

Food and Drug Administration (FDA) Novartis